EG435940 inhibitors are a specialized class of chemical compounds designed to selectively target and inhibit the function of the EG435940 protein, a molecule that plays a role in specific cellular signaling and regulatory mechanisms. EG435940 is involved in mediating processes such as cell communication, signal transduction, and protein-protein interactions within the cell. The inhibition of EG435940 is achieved through the binding of inhibitors to its active or regulatory sites, which subsequently blocks its function. These inhibitors can work through competitive binding, wherein they occupy the same site as the natural substrate, preventing its interaction, or via allosteric binding, where the inhibitor binds to an alternative site that induces conformational changes affecting the protein's functionality. The primary goal in designing EG435940 inhibitors is to ensure specificity, allowing them to precisely target EG435940 while minimizing their effects on similar proteins within the same family or signaling pathway.
The design and development of EG435940 inhibitors utilize advanced structural and computational techniques to achieve their desired properties. Detailed structural information about EG435940 is obtained through techniques such as X-ray crystallography, cryo-electron microscopy (cryo-EM), and nuclear magnetic resonance (NMR) spectroscopy, providing a comprehensive view of the binding pockets and key domains. This information is used in molecular docking studies to screen potential inhibitors and predict their binding affinities and interactions with EG435940. Structure-activity relationship (SAR) analysis helps in understanding how various modifications to the inhibitor's structure impact its binding efficiency and specificity. These inhibitors are often modified to include functional groups that can enhance interactions with specific residues of EG435940, such as polar groups for hydrogen bonding or aromatic rings for hydrophobic stacking. The development also considers factors like solubility, stability, and cellular permeability to ensure effective inhibition within a biological context. The chemical diversity of EG435940 inhibitors allows for flexibility in targeting different aspects of the protein's function, from blocking substrate interactions to modulating protein conformation, thereby providing an important tool for studying the biochemical pathways regulated by EG435940.f
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3-kinase inhibitor, disrupting the PI3K/Akt pathway. By perturbing this pathway, LY294002 indirectly inhibits Vmn1r249 by influencing downstream signaling cascades that regulate its expression and function within the cellular environment. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
PD 169316 is a p38 MAPK inhibitor, disrupting MAPK signaling. Vmn1r249, being downstream in this pathway, is indirectly influenced by SB203580. The inhibition occurs through perturbation of the MAPK signaling cascade, leading to modifications in Vmn1r249 expression and function within the cellular context. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, affecting the JNK signaling pathway. Vmn1r249 is indirectly influenced by SP600125, as it is downstream in the JNK signaling pathway. The inhibition occurs through perturbation of the JNK cascade, leading to modifications in Vmn1r249 expression and function within the cellular context. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, disrupting the MAPK pathway. Vmn1r249 is downstream in this pathway, and its activity is indirectly influenced by PD98059. The inhibition occurs through perturbation of the MAPK signaling cascade, leading to modifications in Vmn1r249 expression and function within the cellular context. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3-kinase inhibitor, perturbing the PI3K/Akt pathway. Vmn1r249 is associated with this pathway, and Wortmannin indirectly inhibits Vmn1r249 by disrupting its activation through the PI3K/Akt signaling cascade, leading to modifications in Vmn1r249 expression and function within the cellular context. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, impacting cell growth and proliferation. Vmn1r249 activity is influenced by mTOR-regulated pathways, and Rapamycin indirectly inhibits Vmn1r249 by disrupting downstream signaling cascades that regulate its expression and function in a cellular context. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a protein phosphatase inhibitor, disrupting cellular phosphorylation dynamics. Vmn1r249 activity is modulated by phosphorylation events, and Calyculin A indirectly inhibits Vmn1r249 by influencing protein phosphatase activity, resulting in altered phosphorylation patterns that impact Vmn1r249 function within the cell. | ||||||